Parliamentary Search

Early day motion tabled by primary sponsor Dai Havard (Labour), on Wednesday, 7 December 2005, in the House of Commons. It is signed by 7 members in total.

THE PHARMACEUTICAL INDUSTRY AND NHS WALES PARTNERSHIP GUIDANCE

That this House welcomes the guidance document (Welsh Health Circular 2005 (016)) promoted by the Welsh Assembly Government, which gives guidance for partnership working between NHS organisations, primary care contractors, the pharmaceutical industry and allied commercial sector; welcomes the principle central to the guidance that partnership working must be conducted for the benefit of patients; supports the development of relationships rather than compelling partnerships; further supports the notion of openness and transparency at the heart of the guidance and the requirement that all partnership arrangements be documented in a register of ledger, available for audit and to the public on request; acknowledges that no partnership is allowed to require the purchase of particular goods or services and that the guidance helps ensure effective partnership working between NHS Wales and the pharmaceutical industry for better health service delivery in Wales; and further welcomes the recent revised United Kingdom pharmaceutical industry Code of Practice supported by the Medicines and Healthcare Products Regulatory Agency revising self-regulation arrangements to help bring confidence to the development of best practice in the involvement of the pharmaceutical industry in developing healthcare.

Amendments

The Early day motion has received an amendment.

THE PHARMACEUTICAL INDUSTRY AND NHS WALES PARTNERSHIP GUIDANCE (1214A1)
The Early day motion has received an amendment sponsored by Paul Flynn (primary, Labour) and tabled on Wednesday, 7 December 2005. It has been signed by 6 members in total.
leave out from `Wales' to end and add `is disappointed with the feeble, self-serving new Code of Practice which allows the drugs industry to continue promoting products with lavish five star hospitality; notes that the British Medical Journal says the code `lacks teeth' and that the editor of the Drugs and Therapeutic Bulletin calls it `fundamentally weak'; is appalled that, following blatant lethal breaches of past codes, the Association of the British Pharmaceutical Industry (ABPI) has never expelled a member company or forced one to publish a corrective statement; is alarmed that adverse reactions to drugs are a major and growing cause of death; and calls on the ABPI to answer the serious criticism of its conduct by the Select Committee on Health with a new code that would adequately protect the public against the perils of mis-prescribed and over-prescribed drugs.

Secondary information

Type
Early day motion
Reference
1214 
1214A1 
Session
2005-06
Other sponsors
Madeleine Moon
Elfyn Llwyd
Hywel Francis
Julie Morgan
Mark Tami
Subjects
Health services Partnerships Standards Wales
Link
View this Early day motion on www.parliament.uk